Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide

BACKGROUND: Tenofovir alafenamide (TAF) is a new formulation of tenofovir disoproxil fumarate (TDF) that was approved in 2015. While clinical trial evidence suggests that TAF has more favorable outcomes related to kidney injury and loss of bone mineral density, TAF also leads to higher lipid levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Anna, Sinclair, Matthew, Hemmersbach-Miller, Marion, Edmonston, Daniel, Wyatt, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098116/
https://www.ncbi.nlm.nih.gov/pubmed/33251997
http://dx.doi.org/10.18553/jmcp.2020.26.12.1582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098116/
https://www.ncbi.nlm.nih.gov/pubmed/33251997
http://dx.doi.org/10.18553/jmcp.2020.26.12.1582

Ejemplares similares